173 related articles for article (PubMed ID: 9778326)
1. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.
Storey RF; Wilcox RG; Heptinstall S
Circulation; 1998 Oct; 98(16):1616-21. PubMed ID: 9778326
[TBL] [Abstract][Full Text] [Related]
2. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
Storey RF; May JA; Wilcox RG; Heptinstall S
Thromb Haemost; 1999 Oct; 82(4):1307-11. PubMed ID: 10544919
[TBL] [Abstract][Full Text] [Related]
3. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
4. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
[TBL] [Abstract][Full Text] [Related]
5. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.
Phillips DR; Teng W; Arfsten A; Nannizzi-Alaimo L; White MM; Longhurst C; Shattil SJ; Randolph A; Jakubowski JA; Jennings LK; Scarborough RM
Circulation; 1997 Sep; 96(5):1488-94. PubMed ID: 9315536
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
Matzdorff A; Voss R
Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
[TBL] [Abstract][Full Text] [Related]
7. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M
Acta Pol Pharm; 2009; 66(3):235-42. PubMed ID: 19645323
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
Kleiman NS; Klem J; Fernandes LS; Rubin H; Challa S; Solomon S; Maresh K; Arora U; Klem E; Buergler J; Mathew S; Browning A; DeLao T
Am Heart J; 2002 Apr; 143(4):585-93. PubMed ID: 11923794
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Ilveskero S; Lassila R
Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
[TBL] [Abstract][Full Text] [Related]
10. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Voss R
J Thromb Thrombolysis; 2001 Oct; 12(2):129-39. PubMed ID: 11729364
[TBL] [Abstract][Full Text] [Related]
11. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
12. Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists.
Rebello SS; Huang J; Faul JD; Lucchesi BR
J Thromb Thrombolysis; 2000 Jan; 9(1):23-8. PubMed ID: 10590185
[TBL] [Abstract][Full Text] [Related]
13. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
Lages B; Weiss HJ
Br J Haematol; 2001 Apr; 113(1):65-71. PubMed ID: 11328283
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of eptifibatide.
Phillips DR; Scarborough RM
Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
[TBL] [Abstract][Full Text] [Related]
15. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
[TBL] [Abstract][Full Text] [Related]
16. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
Harder S; Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Glusa E; Mascelli MA; Marciniak SJ; Just A; Lösche W; Breddin HK
Thromb Res; 2001 Apr; 102(1):39-48. PubMed ID: 11323013
[TBL] [Abstract][Full Text] [Related]
17. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
19. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.
Scholz T; Zhao L; Temmler U; Bath P; Heptinstall S; Lösche W
Platelets; 2002 Nov; 13(7):401-6. PubMed ID: 12487787
[TBL] [Abstract][Full Text] [Related]
20. The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used.
Aalto-Setälä K; Karhunen PJ; Mikkelsson J; Niemelä K
J Thromb Thrombolysis; 2005 Aug; 20(1):57-63. PubMed ID: 16133898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]